Imiglucerase
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Imiglucerase |
| DrugBank ID | DB00053 |
| Brand Names (EU) | Cerezyme |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.52% |
Approved Indication (EMA)
Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: anaemia after exclusion of other causes, such as iron deficiency Thrombocytopenia Bone disease after exclusion
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | Hurler syndrome | 99.52% | DL |
| 2 | Gaucher disease | 99.40% | DL |
| 3 | Scheie syndrome | 99.29% | DL |
| 4 | benign neoplasm of adrenal gland | 99.28% | DL |
| 5 | autosomal ichthyosis syndrome with fatal disease course | 99.24% | DL |
| 6 | cholesteryl ester storage disease | 99.12% | DL |
| 7 | lysosomal storage disease with skeletal involvement | 98.94% | DL |
| 8 | Wolman disease with hypolipoproteinemia and acanthocytosis | 98.93% | DL |
| 9 | Wolman disease | 98.78% | DL |
| 10 | proximal myopathy with extrapyramidal signs | 98.54% | DL |
| 11 | growth hormone insensitivity syndrome with immune dysregulation 2, autosomal dominant | 98.49% | DL |
| 12 | Tay-Sachs disease | 98.41% | DL |
| 13 | familial apolipoprotein C-II deficiency | 98.37% | DL |
| 14 | adult Krabbe disease | 98.36% | DL |
| 15 | encephalopathy due to prosaposin deficiency | 98.30% | DL |
| 16 | Krabbe disease | 98.15% | DL |
| 17 | X-linked lymphoproliferative disease due to SH2D1A deficiency | 98.13% | DL |
| 18 | Cushing disease due to pituitary adenoma | 98.09% | DL |
| 19 | lysosomal acid lipase deficiency | 97.98% | DL |
| 20 | metachromatic leukodystrophy | 97.97% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.